Polymer particles for neutrophil damage
Biodegradable polymeric particles inhibit neutrophil migration and release salicylic acid to treat ALI/ARDS, addressing the ineffectiveness of current treatments by reducing neutrophil-mediated lung injury and improving survival rates.
Patent Information
- Application Number
- JP2021577487
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-07-05
- Filing Date
- 2020-07-02
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2040-07-02
AI Technical Summary
Current pharmacological interventions for acute lung injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are ineffective in reducing mortality, and existing treatments like nitric oxide, exogenous surfactants, and glucocorticoids do not resolve the condition, while mechanical ventilation can cause further lung damage.
The use of biodegradable, biocompatible polymeric particles, such as polyA particles, which inhibit neutrophil function by blocking migration into lung tissues and release salicylic acid to treat inflammatory conditions, including ALI and ARDS, by administering them intravascularly or intravenously, guided by imaging techniques.
PolyA particles effectively reduce neutrophil-mediated lung injury by minimizing neutrophil accumulation and inflammation, improving lung function, and reducing mortality in ALI/ARDS models without adverse effects on the host's ability to clear infections.
Smart Images

Figure 0007591831000001 
Figure 0007591831000002 
Figure 0007591831000003
Abstract
Description
[Technical field]
[0001] [CROSS REFERENCE TO RELATED APPLICATIONS] This application claims priority to U.S. Provisional Patent Application No. 62 / 870,879, filed July 5, 2019, which is incorporated by reference in its entirety.
[0002] Provided herein are therapeutic methods, compositions, systems, and kits using polymer particles as inhibitors of neutrophil function. Such methods include, but are not limited to, methods for preventing, treating, and / or ameliorating inflammatory diseases, infectious diseases, autoimmune diseases, malignant diseases, and other diseases or conditions in which neutrophils may be involved. In some embodiments, the polymer particles are useful in the diagnosis of neutrophil-associated diseases or conditions. [Background technology]
[0003] Neutrophil-based medical conditions include diverse medical conditions including vascular thrombosis, inflammatory arthritis, systemic lupus erythematosus (SLE), atherosclerosis, sepsis, and acute lung injury. For example, acute lung injury (ALI) is a rapidly progressive inflammatory disease characterized by the destruction of the pulmonary endothelial and epithelial barriers, resulting in the accumulation of fluid in the alveolar air spaces. Blood-gas barrier damage impairs gas exchange and reduces lung function. ALI, along with acute respiratory distress syndrome (ARDS), a more severe form of ALI, affects 200,000 patients annually in the United States, with a mortality rate of approximately 40% and a mortality rate of approximately 50-60% by 6 months after discharge. There are no effective pharmacological interventions to reduce the mortality rate of ALI / ARDS. For example, nitric oxide, exogenous surfactant, intravenous prostaglandin E1, and glucocorticoids, which reduce ARDS-associated pulmonary hypertension, have not shown any benefit in resolving ALI / ARDS. The primary treatment for ARDS supports the use of mechanical ventilation for blood oxygenation and CO2 removal, thereby allowing the damaged lungs to heal. However, if not used carefully, mechanical ventilation can cause further damage to the lungs. Thus, management of ALI / ARDS represents an unmet clinical need. Summary of the Invention
[0004] Provided herein are therapeutic methods, compositions, systems, and kits using polymer particles as inhibitors of neutrophil function. Such methods include, but are not limited to, methods for preventing, treating, and / or ameliorating inflammatory diseases, infectious diseases, autoimmune diseases, malignant diseases, and other diseases or conditions in which neutrophils may be involved. In some embodiments, the polymer particles are useful in the diagnosis of neutrophil-associated diseases or conditions.
[0005] In some embodiments, provided herein is a method for treating, alleviating, or preventing recurrence of a neutrophil-mediated inflammatory condition in a patient, comprising administering to the patient a therapeutically effective amount of salicylic acid polyanhydride ester (herein "polyA") particles that hydrolyze to salicylic acid, and a pharma- ceutically acceptable formulation. In certain embodiments, the polyA particles are vascular targeted particles (VTPs). In other embodiments, the polyA particles are non-targeted particles (nTPs). In certain embodiments, the neutrophil-mediated condition is one or more conditions selected from vascular thrombosis, inflammatory arthritis, systemic lupus erythematosus (SLE), atherosclerosis, sepsis, arthritis, acute lung injury (ALI), and acute respiratory distress syndrome (ARDS). In certain embodiments, the patient is a mammal. In other embodiments, the mammal is a human.
[0006] In some embodiments, the administration is intravascular administration. In certain embodiments, the administration is intravenous administration. In further embodiments, the administration is by using a guide catheter, for example, guided by X-ray imaging, ultrasound imaging, computed axial tomography imaging, and / or magnetic resonance imaging.
[0007] In some embodiments, the polyA particles are microparticles, with dimensions of 500-900 nm or more in the case of a sample. In other embodiments, the polyA particles are nanoparticles, with dimensions of, for example, less than 500 nm. In certain embodiments, the polyA particles are spheres. In other embodiments, the microparticles are microparticles. In certain embodiments, the spheres include a smooth surface. In further embodiments, the polyA particles include a variety of polyA particles that differ in size, shape, and / or surface morphology.
[0008] In some embodiments, the invention provides kits comprising a pharmaceutical composition comprising polyA particles and, optionally, instructions for administering the pharmaceutical composition to a patient diagnosed with vascular thrombosis (e.g., venous thromboembolism), inflammatory arthritis, systemic lupus erythematosus (SLE), atherosclerosis, infection (e.g., viral infection), sepsis, acute lung injury arthritis (ALI), and acute respiratory distress syndrome (ARDS).
[0009] In some embodiments, the present invention provides a method for inhibiting a symptom of inflammation, comprising exposing a composition comprising polyA particles to a sample comprising inflammatory cells, the exposure resulting in the inhibition of a symptom of inflammation. In certain embodiments, the sample is from a human. In certain embodiments, the human is diagnosed with vascular thrombosis, inflammatory arthritis, systemic lupus erythematosus (SLE), atherosclerosis, sepsis, acute lung injury arthritis (ALI), and acute respiratory distress syndrome (ARDS). In other embodiments, the sample is selected from the group consisting of a blood sample, a serum sample, a plasma sample, a saliva sample, a urine sample, a synovial fluid sample, a cartilage sample, and a tissue sample.
[0010] In some embodiments, the present invention provides pharmaceutical compositions comprising at least one polyA particle. In certain embodiments, the polyA particle is a targeted polyA particle. In other embodiments, the targeted polyA particle is a polyA VTP. In further embodiments, the polyA particle is a nTP. In certain embodiments, the polyA particle is biocompatible and biodegradable. In a given embodiment, the polyA particle comprises a bioactive molecule.
[0011] In some embodiments, the present invention provides a pharmaceutical composition comprising at least one polyA particle and at least one pharma- ceutically acceptable carrier. In some embodiments, the present invention provides a pharmaceutical composition, wherein at least one polyA particle is made by a method of one or more or all of the steps of: a) dissolving polyvinyl alcohol (PVA) having an average molecular weight of 20-70 kDA in water to produce a 1 wt% PVA solution at pH 6-7; b) dissolving polyA in dichloromethane (DCM); c) adding a solution containing polyA in DCM to the PVA solution over at least 1 hour while mixing at >4000 rpm to produce an emulsion; d) centrifuging the emulsion; e) aspirating the centrifugation solution from the centrifugation pellet; f) resuspending the pellet in deionized water to produce suspended polyA particles; g) washing the suspended polyA particles; h) lyophilizing the washed polyA particles; and i) freezing the lyophilized polyA particles. In other embodiments, polyA particles are modified to be carriers of one or more hydrophobic bioactive compounds or drugs by adding one or more hydrophobic bioactive compounds or drugs to the polyA polymer dissolved in the DCM. In a further embodiment, polyA particles are modified to be carriers of one or more hydrophilic bioactive compounds or drugs by adding one or more hydrophilic bioactive compounds or drugs to the aqueous phase that is emulsified in the polyA polymer dissolved in the DCM and emulsifying the drug-polymer emulsion in a 1 wt% aqueous PVA solution.
[0012] In some embodiments, the present invention provides a pharmaceutical composition comprising at least one PLGA particle and at least one pharma- ceutically acceptable carrier. In some embodiments, the invention provides a pharmaceutical composition, wherein at least one PLGA particle is made by a method of one or more or all of the steps of: a) dissolving polyvinyl alcohol (PVA) having an average molecular weight of 20-70 kDA in water to produce a 0.5 wt% PVA solution at pH 5-6; b) dissolving PLGA (50:50 PLGA (e.g., molecular weight of 6.4 kDA in dichloromethane (DCM)); c) adding a solution containing PLGA in DCM to the PVA solution over at least 1 hour while mixing at >4000 rpm to produce an emulsion; d) centrifuging the emulsion to remove larger particles; e) centrifugation of the supernatant to collect approximately 1.5 um particles; f) aspirating the centrifuged solution from the centrifuged pellet; g) resuspending the pellet in deionized water to produce suspended PLGA particles in solution; h) flash-freezing the solution; i) lyophilizing the PLGA particles; and j) freezing the lyophilized PLGA particles.
[0013] In some embodiments, the invention provides a pharmaceutical composition, wherein at least one polyA VTP particle is made by a method of one or more or all of the steps of: a) suspending polyA particles in 50 mM MES buffer, b) suspending the particles in Neutravidin solution in 50 mM MES, c) adding 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (EDC) solution to the suspended particles, d) adding glycerin to the solution containing polyA particles, e) centrifuging the solution, f) resuspending the polyA particles in PBS, and g) incubating the solution containing polyA particles with biotinylated anti-ICAM-1 in PBS- / - containing 2% BSA.
[0014] The foregoing and other objects, features and advantages of the present invention will become more apparent from the following detailed description which proceeds with reference to the accompanying drawings. [Brief description of the drawings]
[0015] [Figure 1] Scanning electron microscopy (SEM) images of polyA particles fabricated by emulsion solvent evaporation (ESE) method after (A) 0 and (B) 10 days of hydrolysis in water are shown. (C) Release of salicylic acid (SA) from degradable polyA spheres as measured by the fluorescence intensity of SA in the medium over time. [Diagram 2] 1 shows P-selectin expression by resting human platelets with or without polyA particle incubation compared to agonist (ADP)-activated platelets. PolyA non-targeted microparticles do not activate human platelets, thereby demonstrating hemocompatibility. [Diagram 3] Neutrophil counts and cytokine concentrations in pulmonary bronchoalveolar lavage fluid (BALF) of untreated (UT) and lipopolysaccharide (LPS)-treated (ALI) mice. PA = polyA particles, PS = polystyrene particles. Mouse treatments are on the x-axis. [Figure 4] Shown are the bacterial counts in the blood (top) and TNF-α concentrations in the BALF of P. aeruginosa -infected mice (C57BL / 6J) without microparticles (MP) or with polyA MP 6 or 18 hours after infection. [Diagram 5] Neutrophil counts in BALF of P. aeruginosa (Pa)-infected mice (C57BL / 6J) without or with MP treatment at 6 and 18 hours after bacterial infection. BALF samples were taken 24 hours after infection. [Figure 6] Accumulation of anti-intercellular adhesion molecule (ICAM)-1 targeted (shaded) and non-targeted PS MPs in the lungs 24 hours after tail vein injection is shown. [Figure 7] A proposed timeline for mouse particle injection and tissue harvesting relative to the timing of P. aeruginosa infection is shown. [Figure 8]FIG. 1 shows the structures of polymers 1-3 for use in formulating salicylate-based polyA microspheres and their hydrolysis for SA release. [Figure 9] Shown is TNF-a secretion by alveolar macrophages cultured for 2 or 24 hours and then exposed to polyA or PS MPs compared to untreated (UT) macrophages. [Figure 10] We demonstrate the fabrication of poly(lactic-co-glycolic acid) (PLGA) and polyA microsphere particles using a single emulsion and solvent evaporation. [Figure 11] Shown are PLGA and PolyA microspheres and their zeta potential (mV). Zeta potential is a function of the surface charge of the particle relative to the nature of the medium surrounding the particle. This value correlates to how the particle interacts with WBCs. The zeta potential value of PolyA is similar to PLGA, but PolyA has additional beneficial effects in ALI / ARDS. [Figure 12] A) Degradation of polyA particles over time (hours) and B) concentration of salicylic acid (SA) released by incubating the particles in plasma (concentration = 0.6 mg / mL). [Figure 13] Figure 1 shows the injection timeline for a BALB / c model of pulmonary inflammation following lipopolysaccharide (LPS) tracheal instillation. LPS inflames the lungs and induces neutrophil infiltration. Two hours after particle administration, mice are euthanized and the lungs are lavaged to collect cells within the airspaces. Supernatants are analyzed for the presence of inflammatory markers. [Figure 14]BALF percentages of monocytes and neutrophils without LPS injury, percentages of monocytes and neutrophils after LPS injury and without treatment, percentages of monocytes and neutrophils after LPS injury and treatment with polyA particles, and total BALF cell counts in untreated, LPS injury only, and LPS injury / polyA particle treatment are shown. BALB / c mice were induced to have ALI via pulmonary instillation of LPS. Untreated mice did not receive LPS. Data shown in "Untreated monocytes vs neutrophils" are from mice that received no LPS and particle treatment. Data shown in "LPS monocytes vs neutrophils" are from mice that received LPS and no particle treatment. Neutrophils predominate in the BALF. Data shown in "LPS+P monocytes vs neutrophils" are from mice that received LPS and then polyA particle treatment 1 hour after LPS. The number of neutrophils in the lungs is significantly reduced. Total cell counts are displayed in the bar graph. [Figure 15] Comparative IL-6, TNF-α, KC and IL-10 concentrations in uninjured / untreated, LPS-injured / untreated, and LPS-injured / polyA particle-treated mice (LPS+P) are shown. [Figure 16] Comparative MCP-1, albumin, MIP2 and IP10 concentrations in uninjured / untreated, LPS-injured / untreated, and LPS-injured / polyA particle-treated mice are shown. [Figure 17] Cell numbers in BALF samples from untreated BALB / c mice, LPS-injured BALB / c mice, LPS-injured / PS-COOH particle-treated BALB / c mice, LPS-injured / PolyA particle-treated BALB / c mice, LPS-injured / aspirin-treated BALB / c mice, and LPS-injured / vehicle control-treated BALB / c mice are shown, averaged across multiple experiments. PolyA particles protect against lung injury (PA=PolyA). [Figure 18] Shown are cell numbers in BALF samples from untreated, LPS-injured, LPS-injured / PS-COOH particle-treated, LPS-injured / polyA particle-treated, LPS-injured / aspirin-treated, and LPS-injured / vehicle control-treated mice in a single experiment. [Figure 19]Albumin and IL-6 concentrations in BALF supernatants from untreated, LPS-injured, LPS-injured / polystyrene (PS-COOH) particle-treated, LPS-injured / polyA particle-treated, LPS-injured / aspirin-treated, and LPS-injured / vehicle control-treated mice are shown. [Figure 20] IL-10 and KC concentrations in BALF supernatants from untreated, LPS-injured, LPS-injured / polystyrene (PS-COOH) particle-treated, LPS-injured / polyA particle-treated, LPS-injured / aspirin-treated, and LPS-injured / vehicle control-treated mice are shown. [Figure 21] Shown are MCP1 and MIP2 concentrations in BALF supernatants from untreated, LPS-injured, LPS-injured / polystyrene (PS-COOH) particle-treated, LPS-injured, polyA particle-treated, LPS-injured / aspirin-treated, and LPS-injured / vehicle control-treated mice. [Figure 22] TNF-α concentrations in BALF supernatants from untreated, LPS-injured, LPS-injured / polystyrene (PS-COOH) particle-treated, LPS-injured / polyA particle-treated, LPS-injured / aspirin-treated, and LPS-injured / vehicle control-treated mice are shown. [Figure 23] A representative experimental timeline for collection of BALF samples following ALI caused by LPS injection in C57BL / 6J mice without particle treatment is shown. [Figure 24] Comparison intervals of neutrophil infiltration versus percent of immune cells in BALF and total neutrophil counts in blood following LPS injury (ALI) in C57BL / 6J sepsis. [Diagram 25] A representative experimental timeline of BALF sample collection following ALI caused by LPS infusion with 30 mg / kg polyA particles is shown. [Figure 26] The comparative effects of administration of polyA particles 4 hours after LPS on the change in percentage of immune cells and total neutrophil counts in BALF samples compared to treatment with LPS alone, LPS and polystyrene (PS) particles, LPS and PLGA particles, and LPS and polyA particles are shown. [Figure 27] Similar to uninjured untreated mice, we show that polyA particles reduce albumin concentrations in BALF samples when treatment is performed 4 hours after LPS injury, in LPS-injured / PS particle- and LPS-injured / PolyA particle-treated mice compared to LPS-injured / untreated and LPS-injured / PLGA particle-treated mice. Whereas PLGA particles increase lung leakage, polyA particles protect the lung from LTP injury as reflected by lower BALF albumin concentrations. [Figure 28] We show that in LPS-injured / untreated and LPS-injured / PLGA particle-treated C57BL / 6J mice, total cell numbers in BALF samples are highest when treatment is performed 2 hours after LPS injury compared to LPS-injured / PolyA particle-treated mice. PLGA particles have no advantage in total BALF cell numbers, whereas PolyA particles protect the lungs from cellular infiltration when administered 2 hours after infection. [Figure 29] FIG. 1 shows that in C57BL / 6J mice, there is no difference in the treatment of LPS-injured mice between no treatment, treatment with PLGA particles, and treatment with polyA particles when treatment is given 6 hours after LPS injury. [Diagram 30] A representative experimental timeline is shown for mouse P. aeruginosa infection, polyA particle administration, and collection of samples for BALF assay and blood colony forming unit (CFU) enumeration. [Diagram 31] Figure 1 shows comparative concentrations of IL-6 and IL-10 in mice infected with P. aeruginosa without polyA particle administration, with polyA particle administration 6 hours post-infection, and with polyA particle administration 18 hours post-infection, as well as in uninfected control mice. Markers of inflammation are reduced by treatment with polyA particles, with greater benefit when the particles are administered 18 hours post-infection. [Diagram 32]Comparative concentrations of KC and MIP2 in mice infected with P. aeruginosa without polyA particle administration, with polyA particle administration 6 hours post-infection, and with polyA particle administration 18 hours post-infection, as well as in uninfected control mice. Markers of inflammation are reduced by treatment with polyA particles, with a greater benefit when the particles are administered 18 hours post-infection. [Diagram 33] Comparative concentrations of MCP-1 and TNF-α in mice infected with P. aeruginosa without polyA particle administration, with polyA particle administration 6 hours post-infection, and with polyA particle administration 18 hours post-infection, as well as in uninfected control mice are shown. Markers of inflammation are reduced by treatment with polyA particles, with greater benefit when the particles are administered 18 hours post-infection. [Diagram 34] Comparison of total BALF cell counts and total BALF neutrophil counts in P. aeruginosa infected mice without polyA particle administration, with polyA particle administration 6 hours post-infection, and with polyA particle administration 18 hours post-infection, as well as in uninfected control mice with saline injection 18 hours post-infection. Treatment with polyA particles reduces the number of neutrophils, with a greater reduction observed with administration 18 hours post-infection compared to administration 6 hours post-infection. [Diagram 35] Comparison of total BALF cell counts, P. aeruginosa 19660 log BAL CFU / mL counts, and P. aeruginosa 19660 log blood CFU / mL counts 12, 18, 24, 30, and 36 hours after P. aeruginosa infection and without treatment is shown. White blood cells and bacteria increase in the lungs after infection, and bacterial CFU counts in the blood also increase. [Diagram 36]A comparison of P. aeruginosa 19660 log BAL CFU / mL counts and P. aeruginosa 19660 log blood CFU / mL counts at 24 hours post-infection in untreated mice, mice treated intravenously with intravenous PolyA particles, and mice treated with intravenous saline assayed at 18 hours post-infection is shown. PolyA particles reduce P. aeruginosa 19660 log BAL CFU / mL counts and P. aeruginosa 19660 log blood CFU / mL counts at 24 hours post-infection. [Figure 37] Figure 1 shows the comparative benefit of polyA particle treatment on daily survival up to 10 days after P. aeruginosa infection. Mice were infected with P. aeruginosa at 18 hours post-infection. One subset was treated with polyA particles ("Particle A iv") and a second subset was not treated. The polyA treated subset of mice had a 60% survival rate compared to 40% survival in the untreated group. [Figure 38] Flow cytometry histogram plots of polyA-avidin and polyA anti-ICAM-1 VTPs are shown. [Figure 39] 1 shows the effect of polyA particle injection on P. aeruginosa lung infection in C57BL / 6J mice, comparing total cells in BALF at 24 hours after infection between infected mice and saline controls after polyA injection at 6 or 18 hours, PLGA injection at 18 hours, or polystyrene injection at 18 hours. [Diagram 40] 1 shows that the concentration of IgM in BALF is reduced in infected mice by treatment with polyA particles. [Diagram 41] Comparative concentrations of inflammatory cytokines by ELISA quantification of (a) TNF, (b) IL-6, (c) IL-10, and (d) IP-10 produced by alveolar macrophages in response to 3 or 24 hours of LPS treatment with or without the addition of polyA or polystyrene (PS) particles. [Diagram 42]Figure 1 shows post-infection survival of P. aeruginosa infected mice (N=5 for each group) with or without polyA MP injection for 18 hours. 2E8 particles were injected into each mouse for each particle type. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] [Definitions and Methods] Although the present invention will be described in conjunction with certain representative embodiments, it will be understood that the present invention is not limited to these illustrative examples. Those skilled in the art will recognize that many methods and materials similar or equivalent to those described herein can be used to practice the present invention. The present invention is not limited to the methods and materials described.
[0017] Unless otherwise defined, technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the present invention belongs. Definitions of common terms in molecular biology can be found in Benjamin Lewin, Genes V, Oxford University Press, 1994 (ISBN 0-19-854287-9), Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9), and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8). Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice of the present invention, specific methods, devices, and materials are described herein. It will be further understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values given for nucleic acids or polypeptides are provided by way of illustration.
[0018] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods, devices, and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described.
[0019] As used in this disclosure, including the appended claims, the singular forms "a," "an," and "the" include plural references unless the content clearly dictates otherwise and are used synonymously with "at least one" and "one or more." Thus, reference to "polyA MP" includes a mixture of polyA MP, and so forth.
[0020] As used herein, the term "about" denotes an insignificant modification or variation of a numerical value such that the basic function of the item to which the numerical value is associated is not altered.
[0021] As used herein, "protein" is used synonymously with "peptide," "polypeptide," or "peptide fragment." A "purified" polypeptide, protein, peptide, or peptide fragment is substantially free of cellular material or other contaminating proteins from the cell, tissue, or cell-free source from which the amino acid sequence is obtained, or is substantially free of chemical precursors or other chemicals when chemically synthesized.
[0022] As used herein, "inflammatory disease" refers to a disease or condition associated with an inflammatory response. The inflammatory response can be acute and / or chronic. In some embodiments, chronic inflammation is associated with increased neutrophil numbers and / or activity. Non-limiting exemplary inflammatory diseases that may be treated with the polyA particles described herein include rheumatoid arthritis, juvenile idiopathic arthritis, systemic onset juvenile idiopathic arthritis, osteoarthritis, sepsis, asthma, interstitial lung disease, inflammatory bowel disease, systemic sclerosis, intraocular inflammation, Graves' disease, endometriosis, systemic sclerosis, adult onset Still's disease, amyloid A amyloidosis, polymyalgia rheumatica, remitting seronegative symmetrical synovitis with pitting edema tending to resolve spontaneously, Behcet's disease, uveitis, graft versus host disease, venous thromboembolism, ALI / ARDS, and TNFR-associated periodic syndromes.
[0023] As used herein, "infectious disease" refers to a disease or condition caused by a pathogen, such as a bacterium, a virus, a fungus, etc. Non-limiting exemplary infectious diseases that may be treated with the polyA particles described herein include bacterial infections, viral infections, fungal infections, rickettsial infections, and parasitic infections. In some embodiments, the viral infection is a respiratory viral infection, including, for example, influenza virus infection, coronavirus infection (e.g., severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)), and respiratory syncytial virus infection.
[0024] As used herein, "autoimmune disease" refers to a disease or condition resulting from an inappropriate immune response against the body's own components, such as tissues and other components. In some embodiments, neutrophil counts and activity are elevated in autoimmune diseases. Non-limiting exemplary autoimmune diseases that may be treated with the polyA particles described herein include systemic erythromatosis, systemic sclerosis, polymyositis, vasculitic syndromes including giant cell arteritis, Takayasu phlebitis, cryoglobulinemia, myeloperoxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis, rheumatoid vasculitis, Crohn's disease, relapsing polychondritis, acquired hemophilia A, and autoimmune hemolytic anemia.
[0025] As used herein, "neutrophil-mediated condition or disease" refers to a disease or condition in which at least some of the symptoms and / or progression of the disease or condition are caused by neutrophil accumulation and / or activity. Non-limiting exemplary neutrophil-mediated diseases or conditions include inflammatory diseases, malignant diseases (including cancer and cancer-related diseases), infectious diseases, and autoimmune diseases. Further non-limiting exemplary neutrophil-mediated diseases include, but are not limited to, Castleman's disease, ankylosing spondylitis, coronary heart disease, rheumatoid arthritis cardiovascular disease, pulmonary arterial hypertension, chronic obstructive pulmonary disease (COPD), atopic dermatitis, psoriasis, sciatica, venous thrombosis, type II diabetes, obesity, giant cell arteritis, acute graft-versus-host disease (GVHD), non-ST-segment elevation myocardial infarction, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, neuromyelitis optica, chronic glomerulonephritis, and Takayasu's arteritis.
[0026] As used herein, "modulate" means to alter, either by increasing or decreasing, the number and / or activity of a cell. The term "inhibit" as used herein means to prevent or decrease the number and / or activity of a cell. As used herein, the cells to be modulated are neutrophils.
[0027] As used herein, the term "biological activity" refers to an effect on one or more cellular or extracellular processes (e.g., via binding, signaling, etc.) that may affect physiological or pathophysiological processes.
[0028] As used herein, the term "pharmaceutical acceptable" means approved by a federal or state regulatory agency or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in animals, and more specifically in humans. The terms "carrier" and / or "formulation" refer to a diluent, adjuvant, excipient, or vehicle with which a therapeutic is administered, including, but not limited to, sterile liquids such as water and oils.
[0029] "Pharmaceutically acceptable salts" or "salts" are products of the disclosed compounds that contain an ionic bond, typically produced by reacting the disclosed compounds with either an acid or base suitable for administration to an individual. Pharmaceutically acceptable salts may include, but are not limited to, acid addition salts including hydrochloride, hydrobromide, phosphate, sulfate, hydrogen sulfate, alkylsulfonate, arylsulfonate, arylalkylsulfonate, acetate, benzoate, citrate, maleate, fumarate, succinate, lactate, and tartrate salts, salts with alkali metal cations such as Li, Na, K, alkaline earth metals such as Mg or Ca, or organic amine salts.
[0030] A "pharmaceutical composition" is a formulation that contains polyA polymer particles in a form suitable for administration to an individual. A pharmaceutical composition is typically formulated to be compatible with its intended route of administration. Examples of routes of administration include, but are not limited to, oral and parenteral, such as intravenous, intradermal, subcutaneous, inhalation, topical, transdermal, transmucosal, intraarticular, intraocular, and rectal administration.
[0031] As used herein, the term "therapeutically effective amount" generally refers to the amount required to prevent, reduce or improve at least one symptom of the disorder or condition being treated as described herein. The phrase "therapeutically effective amount" refers to the polyA particle dosage when it relates to the polyA particles of the present disclosure, where the polyA particles provide a specific pharmacological response when administered to a significant number of individuals in need of such treatment. It is emphasized that a therapeutically effective amount of polyA particles administered to a particular individual in a particular instance is not necessarily effective for treating the conditions / diseases described herein, even if such a dose would be considered therapeutically effective by those skilled in the art.
[0032] As used herein, the term "second agent" refers to a therapeutic agent other than the polyA particles according to the present invention. In certain instances, the second agent is an anti-inflammatory agent.
[0033] As used herein, the term "sepsis" refers to the presence of harmful microorganisms in the blood.
[0034] The term "co-administration" refers to the administration of at least two agents(s) (e.g., polyA particles) or therapies to a subject. In some embodiments, the co-administration of two or more agents / therapies is simultaneous. In other embodiments, a first agent / therapy is administered prior to a second agent / therapy. Those skilled in the art will appreciate that the formulations and / or routes of administration of the various agents / therapies used may vary. Appropriate dosages for co-administration can be readily determined by those skilled in the art. In some embodiments, when agents / therapies are administered simultaneously, each agent / therapy is administered at a lower dosage than would be appropriate for their administration alone. Thus, co-administration is particularly desirable in embodiments where co-administration of agents / therapies reduces the required dosage of a known potentially harmful (e.g., toxic) agent(s).
[0035] The term "combination therapy" includes the administration of an anti-inflammatory agent (e.g., polyA particles) and at least a second agent as part of a specific therapeutic regimen intended to produce a beneficial effect from the interaction of these therapeutic agents. The beneficial effect of this combination includes, but is not limited to, a pharmacokinetic or pharmacodynamic interaction resulting from the combination of therapeutic agents. The administration of these therapeutic agents in combination is typically carried out over a defined period of time (usually minutes, hours, days or weeks depending on the combination selected). "Combination therapy" may be intended to include the administration of two or more of these therapeutic agents as part of separate monotherapy regimens that incidentally and optionally result in the combination of the present invention, although this is not generally the case. "Combination therapy" is intended to include the administration of these therapeutic agents in a sequential manner, i.e., each therapeutic agent is administered at a different time, as well as the administration of these therapeutic agents, or at least two of these therapeutic agents, in a substantially simultaneous manner. Substantially simultaneous administration can be achieved, for example, by administering to the subject a single capsule or injection having a fixed ratio of each therapeutic agent, or by multiple single capsules or injections for each of the therapeutic agents. The sequential or substantially simultaneous administration of each therapeutic agent may be effected by any suitable route, including, but not limited to, oral, intravenous, intramuscular, intra-articular, corneal, topical, and direct absorption through mucosal tissue. The therapeutic agents may be administered by the same route or by different routes. For example, the first therapeutic agent of the selected combination may be administered by intravenous injection, while the other therapeutic agent of the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally, or all therapeutic agents may be administered by intravenous injection. The order in which the therapeutic agents are administered is not narrowly important. "Combination therapy" may also include administering the above therapeutic agents in further combination with other biologically active ingredients and non-drug therapies (e.g., surgery or radiation therapy). When the combination therapy further includes a non-drug treatment, the non-drug treatment may be performed at any suitable time, as long as a beneficial effect from the interaction of the combination of the therapeutic agent and the non-drug treatment is achieved.For example, in appropriate cases, the non-drug treatment may be temporarily removed from the administration of the therapeutic agent, perhaps for days or weeks, and still achieve beneficial effects.
[0036] Ranges provided herein are understood to be shorthand expressions of all values within the range, for example, a range of 1 to 50 is understood to include any number, combination of numbers, or subrange from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (as well as fractions thereof unless the context clearly dictates otherwise). Any concentration range, percentage range, ratio range, or integer range should be understood to include any integer value within the recited range, and fractions thereof (e.g., tenths and hundredths of integers), where appropriate, unless otherwise indicated. Also, any numerical range recited herein relating to any physical characteristic, such as polymer subunits, size or thickness, should be understood to include any integer within the recited range, unless otherwise indicated.
[0037] [Detailed Description] Provided herein are therapeutic methods, compositions, systems, and kits using polymer particles as inhibitors of neutrophil function. Such methods include, but are not limited to, methods for preventing, treating, and / or ameliorating inflammatory diseases, infectious diseases, autoimmune diseases, malignant diseases, and other diseases or conditions in which neutrophils may be involved. In some embodiments, the polymer particles are useful in the diagnosis of neutrophil-associated diseases or conditions.
[0038] [ALI / ARDS] A number of complex pathologies lead to ALI / ARDS. Either direct or indirect injury initiates ALI / ARDS with no difference in overall mortality. Direct lung injury occurs due to pathologies that begin in the lung, e.g., pneumonia, inducing activation of pulmonary macrophages followed by damage to the lung epithelium. A cascade of inflammatory events in the lung then leads to inflammation of the pulmonary endothelium and recruitment of primary leukocytes from the blood to the lung, thereby propagating the injury. Indirect injury results from extrapulmonary pathologies, e.g., sepsis or trauma, where the disease results in systemic inflammation that initiates rapid leukocyte migration to the lung. Leukocyte migration damages the pulmonary endothelium and ultimately the lung epithelium. Regardless of the primary cause of ALI, the outcome is damaged alveolar epithelium, leading to rapid infiltration of the alveoli with immune cells and protein-rich fluid, resulting in reduced lung function.
[0039] [Neutrophils in ALI / ARDS] The inflammatory cascade in ALI / ARDS induces capillary endothelium to express leukocyte adhesion molecules (LAMs) that promote rapid migration of circulating blood neutrophils. LAMs, including selectins, intracellular adhesion molecule (ICAM)-1, and vascular cell adhesion molecule (VCAM)-1, promote rapid migration of circulating white blood cells (WBCs) and leukocytes in lung tissue. Neutrophils are the most abundant WBCs, accounting for 60%-70% of the WBC count, and are the most efficient initial responders in acute inflammation. Thus, neutrophils are the primary cell type in bronchoalveolar lavage fluid (BALF) from ARDS patients, and disease severity correlates with the concentration of neutrophils in BALF samples. Neutrophils are the primary perpetrators of inflammation in ALI / ARDS that cause damage in at least two ways. First, excessive migration of neutrophils to the lungs is responsible for the disruption of the alveolar-capillary barrier leading to pulmonary edema. Second, neutrophils accumulate in lung tissue and alveolar air spaces, releasing damaging pro-inflammatory and pro-apoptotic factors that affect resident cells and cause further damage to the lung. Stopping neutrophils from negatively contributing provides an opportunity for targeted treatment of ALI / ARDS and other inflammatory conditions. Drugs that block or suppress LAM expression, such as lysophilin and talactoferrin, have failed in clinical trials. The CD11b / CD18 (Mac-1) integrin is important in Escherichia coli (E. coli) LPS- and Pseudomonas (P.) aeruginosa-induced ALI, but blocking CD18 reduces neutrophil pulmonary migration by only 60%.
[0040] In experiments conducted during the course of development of embodiments of the present invention, it has been discovered that non-targeted and vascular targeted nanoparticles and microparticles (VTPs) (e.g., particles with surfaces bound with antibodies or ligands (e.g., anti-E-selectin antibodies, anti-ICAM-1 antibodies, anti-VCAM-1 antibodies, etc.) that target proteins expressed on the vascular wall, as well as other peptides and carbohydrates that bind to selectins and LAMs) halt their destructive role in ALI / ARDS by passively (i.e., without active pharmaceutical ingredients (APIs)) and rapidly blocking neutrophil accumulation in inflamed tissues in ALI / ARDS. Polystyrene (PS) VTPs in the human bloodstream interact with and reduce neutrophil vascular wall adhesion to monolayers of activated endothelial cells (ECs) in vitro in parallel plate flow chambers. Selectin-targeted polystyrene (PS) VTPs result in a nearly 100% reduction in neutrophil adhesion by physically covering the EC surface, thus blocking neutrophil attachment. At high particle concentrations, neutrophil adhesion is prevented by both physical coverage of the EC surface and by free stream particle-cell interactions (approximately 55% reduction in WBC adhesion with non-targeted non-adhesive particles at 108 particles / ml of blood), indicating that PS-VTP in human blood alters neutrophil-vessel wall adhesion and provides new opportunities for anti-inflammatory therapy in ALI where rapid intervention is desirable. In the lipopolysaccharide (LPS) mouse model of ALI, LPS administered to the lungs of healthy mice induces rapid recruitment of neutrophils to the lungs. Treatment of LPS-ALI mice with 2 μM PS microparticles administered by tail vein injection at 30 mg / kg 1 h after LPS injection reduced total lung lavage neutrophil counts from LPS-only mice by 93%, to 2.9 × 10 6LPS-treated mice receiving 500 nm PS-VTP had a reduction in total BALF neutrophils to 6.4 x 105, equivalent to a 98% reduction from LPS-only mice. Both PS particle treatment groups were not statistically different from untreated (no LPS) mice. Although both particle sizes induced the same level of neutropenia in LPS-treated mice, microparticles reduced lung neutrophil numbers more efficiently compared to nanoparticles, considering 64-fold more nanoparticles were injected in numbers equivalent to mass-based dosing. LPS injection alone does not result in monocyte translocation or changes in absolute numbers of macrophages in the lung with or without particle injection. Although the methods, compositions, kits and systems of the present invention are not limited to a particular mechanism, the polymer particles appear to achieve therapeutic benefit against unwanted neutrophil accumulation in air spaces in ALI / ARDS through physical interactions that reduce leukocyte adhesion to inflamed endothelium (e.g., blood flow impingement that disrupts leukocyte adhesion, specific binding to LAM expressed by endothelium in inflamed tissues in competition with leukocytes for binding sites, particle phagocytosis / internalization that alters leukocyte phenotype, and translocation of neutrophils from lungs and blood to liver). These features are distinct from the use of polymer particles as drug or bioactive compound carriers, i.e., VTCs, configured for delivery of bioactive molecules (e.g., protein or peptide antigens directed to cells of adaptive immunity) or pharmacological molecules. Thus, neutrophil-targeted polymer particles provide previously unknown therapies for neutrophil-mediated inflammatory and other conditions, including vascular thrombosis, inflammatory arthritis, systemic lupus erythematosus (SLE), atherosclerosis, sepsis, and ALI / ARDS.
[0041] The present invention provides, for example, polymer particles formed from biodegradable, biocompatible polyA polymers that block neutrophil migration. The non-toxic degradation products of polyA polymers (i.e., salicylic acid) are themselves anti-inflammatory, with the added benefit of polyA particles for treatment in ALI / ARDS. For example, polyA particles are targeted to release salicylic acid locally to block neutrophil migration to the lung airways in ALI / ARDS and further treat lung injury. In this way, it is contemplated that local neutrophil adhesion at the site of inflammation is stopped, neutrophil migration to lung tissue and air spaces is rapidly and efficiently impeded with minimal impact on the system, host protective response is maintained, and biodegradation is rapid. The direct action of PolyA particles on neutrophils within the pulmonary vasculature and other tissues after intravascular injection, rather than indirectly blocking adhesion or signaling molecules, ensures that PolyA polymer particles will function regardless of whether neutrophils are the primary direct or indirect cause of ALI / ARDS or other conditions in which neutrophils are involved in the pathogenesis of vascular thrombosis, inflammatory arthritis, systemic lupus erythematosus (SLE), atherosclerosis, infections, and sepsis.
[0042] [Poly A microparticles] FIG. 1c and FIG. 8 show the structures of polyA polymers where "R" corresponds to linkers ranging from low molecular weight straight chain hydrocarbons to branched aliphatic hydrocarbons. PolyA polymer particles are biocompatible (Reynolds, MA, A. Prudencio, MEAichelmann-Reidy, K. Woodward, and KEUhrich. Non-steroidal anti-inflammatory drug (NSAID)-derived poly(anhydride-esters) in bone and periodontal regeneration. Curr Drug Deliv, 2007.4(3):p.233-9; Bryers, JD, RA Jarvis, J. Lebo,. Prudencio, TR Kyriakides, and K. Uhrich. Biodegradation of poly(anhydride-esters) into non-steroidal anti-inflammatory drugs and their effect on Pseudomonas aeruginosa biofilms in vitro and on the foreign-body response in vivo. Biomaterials, 2006.27(29):p.5039-48) and stable under dry storage conditions (Deronde, BM, AL Carbone and KEUhrich, Storage Stability Study of Salicylate-based Poly(anhydride-esters)Polym Degrad Stab,2010.95(9):p.1778-1782). When placed in aqueous solution, the polymer degrades to release salicylic acid (SA), which retains its anti-inflammatory properties. In some embodiments, emulsion solvent evaporation (ESE) technique is used to create degradable microparticles (Figure 1A) of polyA polymer with adipic acid as the linker, i.e. R=(CH2)4 and MW approx. 20 kDA. (Figure 8) 20 mg of polyA polymer (Mw=approx. 20 kDa) is dissolved in 20 mL of dichloromethane (oil phase) and the solution is emulsified in an aqueous solution of 1 wt% PVA (75 ml, aqueous phase).The oil phase is slowly injected through a syringe needle and the emulsion is continuously stirred for up to 2 h, which allows the oil droplets to harden. The resulting polyA particles are washed twice by centrifugation and dried by lyophilization. The particles are stored at -40 °C until use. The generated polyA particles undergo hydrolysis (Figure 1C) and sustained release of salicylic acid (SA) (Figure 1C).
[0043] In some embodiments, the polyA particles of the present invention are spherical. In certain embodiments, the polyA particles range in diameter from 100 nm to 2 um. In certain embodiments, the polyA spheres are made via the oil-in-water ESE method described above with adipic acid linker (R=(CH2)4) and a polymer with a molecular weight (Mw) of about 20 kDa. In other embodiments, the polyA particles are non-spherical and / or irregular in shape and surface morphology, including, for example, rods, ellipses, stars, cones, cubes, etc. In further embodiments, the polyA particles in a single dose are uniform in size, shape, and surface morphology. In yet further embodiments, the polyA particles in a single dose are non-uniform in size, shape, and surface morphology. In some embodiments, the processing parameters, such as emulsification rate and oil phase polymer concentration, are adjusted to achieve the desired average polyA particle size, for example, 200 nm and 2 μm. Scanning electron microscope (SEM) images of dried particles are used to assess particle surface morphology, as well as particle size and zeta potential (ZP, a measure of surface charge) determined using a Malvern Zetasizer Nano-ZS. In certain embodiments, polyA particle degradation profiles are determined via spectrophotometry in phosphate buffered saline (PBS) and plasma at pH 7.4 and 37° C. (FIG. 1C), and changes in solution pH are monitored as the polyA particles degrade. In further embodiments, polyA particle size, morphology, uniformity and shape are quantified by flow cytometry and optimized for the ability to bind to human umbilical vein endothelial cells from flowing whole blood (e.g., human whole blood) to predict in vivo functionality.
[0044] In some embodiments, the blood compatibility of polyA particles with human cells is optimized in vitro. In certain embodiments, the potential for polyA particle toxicity in blood is evaluated and optimized via platelet activation and hemolysis assays. For platelet activation assays, polyA particles are incubated for 1 hour in platelet-rich plasma (PRP) obtained via centrifugation of whole blood. PRP samples exposed to polyA particles are then stained with anti-CD41 / 61 (PE) and anti-CD62P (APC) and P-selectin expression is determined via flow cytometry. P-selectin expression on resting platelets is minimal, and high P-selectin expression on platelets is an indication of activation. For hemolysis assays, polyA particles are combined with isolated human RBCs in PBS buffer for 15, 30, 60, and 120 minutes, and then the samples are centrifuged to pellet intact RBCs and particles. Supernatants from Poly A particle-incubated samples are assessed via spectrophotometer for hemoglobin concentration as an indicator of RBC lysis. Non-targeted Poly A microparticles do not activate human platelets (Figure 2) or induce hemolysis when placed in human blood.
[0045] In some embodiments, the polyA particle elements of the invention are optimized for favorable in vivo biodistribution and biocompatibility by visualization of adhesion of polyA microparticles to inflamed venules in experimental animal models of human diseases and conditions, along with healthy control animals. In vivo adhesion to inflamed vessel walls is detected with fluorescent labels within the polyA particle matrix. Intravital microscopy (IVM) is used to visualize adhesion of polyA particles and evaluate their effect on adhesion of circulating neutrophils in vivo. Healthy C57BL / 6J mice of mixed sex (50:50) are used. In control assays, (1) polyA particles are observed in non-inflamed mice (negative) and neutrophil adhesion is quantified in mice with mesenteric inflammation but not injected with particles (i.e., vehicle only). PolyA particles are evaluated in mice with inflammation. PolyA particles are injected at 10,000 sites / μm 2The microspheres are targeted via 1000 μg of anti-ICAM-1 (YN1 / 1.7.4, mouse) antibody. This antibody density is sufficient to mediate firm arrest of the microspheres to the inflamed vessel wall in vivo. The particles are injected at approximately 15 mg / kg in sterile PBS to achieve a concentration of approximately 1.2 mg / kg or approximately 45 mg / m, sufficient to reduce neutrophils in the BALF of ALI mice. 2 This dose is consistent with the preclinical dose evaluated in mice, and doses of 35-50 mg / m2 of PEGylated liposomal doxorubicin are routinely used in Phase II human clinical trials.
[0046] For the mesenteritis model, mice are anesthetized and a lateral tail vein catheter is placed for intravenous injection of antibodies, particles, and additional anesthetic reagents as needed. Mice are placed on a microscope with a 37 °C heated stage, and the mesentery is visualized on a glass coverslip via a midline incision. After vascular selection, to ensure that neutrophils are the predominant cells blocked from adhering to inflamed vessels, neutrophils are tagged in vivo by direct injection of fluorescent Ly6G antibodies (5 μg of Gr-1 or 1A8) prior to particle injection. Acute inflammation is induced by topical application of 10 μL of 200 μg / mL TNF-α in PBS. Particles are injected 10 min after TNF-α activation. Mesenteric vessels are imaged for particle and cell adhesion for up to 60 min via an inverted fluorescence microscope (Zeiss Axio Observer Z1 Marianas Microscope) with a 25x oil objective. Images are recorded continuously in bright field and green fluorescence every 10 ms using Slidebook 6 software. Data on polyA particle adhesion and neutrophil blockade are collected <5, 10, 15, and 60 min after particle injection. At 60 min, multiple vessels are imaged for up to 2 min each in the same animal to confirm the observed particle adhesion and to ensure that neutrophil blockade is not an artifact of a single vessel selected for imaging. At the end of IVM imaging, mice are euthanized and the distribution of polyA particles in vital organs such as lungs, liver, heart, kidneys, and spleen is assessed and compared between inflamed and non-inflamed mice. Whole organ scans assessing relative total fluorescence are obtained using an Odyssey CLx Infrared Imaging System (LI-COR), and single cell suspensions of all organs are then obtained via collagenase homogenization that are analyzed via cytometry. Homogenized liver samples are evaluated for changes in leukocyte populations and cytokines.
[0047] In some embodiments, the components of the polyA particles of the present invention are optimized for favorable in vivo blood circulation and clearance. A kinetic assay is performed in healthy mice, and mouse blood is sampled 5 minutes, 15 minutes, and 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, and 24 hours after polyA particle injection (e.g., 15 mg / kg), and particle numbers are evaluated to characterize the clearance rate of polyA particles from the bloodstream. In certain embodiments, polyA particles are made with ICAM-1 antibodies, and the components of the polyA particles are evaluated and compared. Control mice include mice treated with PBS only and mice treated with non-targeted 2 μm polyA particles. At the desired times, 10 μL of blood is collected and scanned (e.g., by fluorescent scanning) for polyA particles on an Odyssey CLx Infrared imaging system. Values for pharmacokinetic parameters such as plasma half-life, volume of distribution, and clearance are obtained from plots of plasma concentration versus time profiles using PKSolver, with the data fitted to a two-compartment model. 24 hours after particle injection, mice are euthanized and particle distribution and cytokine levels are assessed in extracted vital organs. Portions of vital organs are subjected to hematoxylin and eosin (H&E) staining and blindly scored by a clinical veterinary pathologist for any signs of tissue damage / inflammation associated with injection of polyA particles.
[0048] In some embodiments, the elements of the polyA particles of the present invention are optimized for a favorable profile of biocompatibility in healthy mice. The polyA particle injection is performed and blood counts are measured. Mice are euthanized or returned to their cages 2, 30, and 60 minutes after particle injection and observed for weight and behavioral changes over a period of 7 days compared to baselines before particle injection. Time points are selected based on evidence that neutrophil counts return to baseline by 1 hour after particle injection when the particles are cleared from the bloodstream. At targeted time intervals, mice are euthanized via cardiac puncture for blood collection and vital organs are removed. Blood is measured for cell counts (platelets, neutrophils, monocytes, and lymphocytes), as well as hematocrit and hemoglobin levels compared to PBS control mice, along with levels of platelet activation and cell apoptosis. The weight of each organ is recorded and particle composition is evaluated in tissue homogenates. Histology is used to detect whether there is damage or scarring to vital organs. Signs of inflammation are evaluated via measurement of cytokine expression levels. Experiments conducted during the development of the present invention show that (1) polyA particles bind to inflamed blood vessels and reduce neutrophil adhesion, and (2) polyA particles show minimal toxicity in mice, with 100% of mice with LPS-induced ALI surviving at least 48 hours after polyA particle injection. In other embodiments, polyA coated with anti-ICAM-1 is used. In other embodiments, alternative routes or administrations are used, including, for example, intravascular, intraarterial, intravenous, catheter-based, pulmonary artery catheter-based, interventional radiology, ultrasound-guided, MRI-guided, surgically-guided, laparoscopically-guided, bronchoscopy-guided, intratracheal, intramuscular, subcutaneous, enteral, rectal, inhalation, intraperitoneal, intraarticular, intraspinal, intraventricular, intrableb, intraparenchymal, etc. In other embodiments, the sample is incubated with an antibody against an isotype of anti-ICAM-1 bound to polyA VTP.
[0049] In some embodiments, the components of the polyA particles of the invention are optimized for their therapeutic benefits. In certain embodiments, the therapeutic impact of polyA particles is compared in a Pseudomonas (P.) aeruginosa mouse model of ARDS. P. aeruginosa, a gram-negative bacterium, is the second most common cause of pneumonia in hospitalized patients and causes lung damage with a mortality rate of 60-90% in mechanically ventilated patients. The mouse model of P. aeruginosa-induced lung injury replicates the histological and immunological characteristics of ARDS in humans, where 46-51% of ARDS cases result from pulmonary bacterial infection. This model evaluates the protective effect of polyA particles against lung injury and the possible deleterious effects of the particles on the innate protective response. Mixed-sex (50:50) strain C57BL / 6J mice and P. aeruginosa 19660 obtained from ATCC are used.
[0050] In some embodiments, the polyA particle elements of the invention are optimized for the timing of neutrophil extravasation and barrier disruption. The time course of neutrophil migration to the lungs is assessed after P. aeruginosa challenge in mice in the absence of polyA particles to establish a baseline to guide the timing of polyA particle intervention. Example 2 shows the importance of the "time post-infection" at which polyA particles are injected to achieve significant therapeutic benefit (Figure 5) linked to the kinetics of neutrophil migration to the BALF and the development of lung injury. The time at which mice are infected with P. aeruginosa and euthanized is varied, e.g., 6, 12, 18, 24, 30, and 36 hours after bacterial infection. The 36 hour upper limit was chosen, taking into account the 20% survival rate 48 hours after P. aeruginosa infection in C57BL / 6J mice, with a survival rate of approximately 70% at 24 hours. BALF, lung tissue, and blood are analyzed for cell content, bacteria (CFU), and inflammatory markers. White blood cell counts are obtained via flow cytometry, where BALF single cell suspensions or blood are stained with a panel of fluorescent antibodies to identify different cell populations. Neutrophils, monocytes, lymphocytes, macrophages, and dendritic cells are stained within the BALF. Changes in levels of inflammatory cytokines (e.g., IL-6, IL-12, MIP-2, MCP-1, IL-17KC, IL-10, TNF-α, and IL-1β) in BALF supernatants and plasma via ELISA are compared. BALF albumin and IgM levels are quantified to assess alveolar epithelial integrity in infected mice. Major organs, including lungs, liver, heart, kidneys, and spleen, are harvested and assessed for bacterial CFU, white blood cells, and inflammatory cytokines. All observed cell counts and cytokine levels are compared to baseline in uninfected (vehicle only) mice.
[0051] In some embodiments, the polyA particle elements of the present invention are optimized for the impact of timing of polyA particle administration on reducing lung injury in P. aeruginosa-induced ALI / ARDS. The ability of polyA particles to ameliorate lung injury in P. aeruginosa-infected mice is compared to the extent of injury characterized for "no particle" treatment via assessment of leukocyte counts, cytokine levels, and bacterial CFU in BALF and lungs, blood, and other major organs. VTPs of different diameters are evaluated (e.g., 200 nm and 2 μm VTPs for mouse anti-ICAM-1 (YN1 / 1.7.4)). Unlike non-targeted microparticles, this antibody-coated PS VTP is retained in the lungs of ALI mice for up to 24 hours (Figure 6). Mice are treated with VTP (e.g., at 15 mg / kg or other doses) and injected at various times 6, 12, 18, 24, and 30 hours after infection. Regardless of particle injection interval, mice are euthanized 36 hours post-infection with a fixed interval (Figure 7). The ability of antibody-targeted polyA particles (anti-ICAM-1 or anti-E-selectin or anti-VCAM-1) to enhance therapeutic impact is evaluated compared to administration of non-targeted 2 μm polyA at the 18-hour time point, which has been shown to reduce BALF neutrophils and blood CFU in P. aeruginosa-infected mice (Example 2). BALF cells are counted and changes in albumin / IgM levels, bacterial CFU, and inflammatory cytokines in BALF supernatants are measured versus polyA injection time. Lung tissue is evaluated for particle content (i.e., by whole organ scan histology, and tissue homogenates), as well as bacterial CFU, cytokines, and white blood cell counts. The extent of lung injury via blinded scoring of H&E stained lung sections for epithelial thickening, airway epithelial necrosis, and intra-alveolar edema is evaluated for different MP injection times compared to "no particulate" controls.
[0052] In some embodiments, the components of the polyA particles of the present invention are optimized for the time after particle injection when the animals are euthanized by comparing the degree of lung damage and bacterial spread observed. 2 μm sized polyA particles are administered at fixed "times after infection" of 6 and 18 hours, and BALF and major organ cell / cytokine / CFU / particle counts are analyzed at various times, 6, 12, 18, and 24 hours after particle injection (i.e., mice are euthanized) (Figure 7). The liver is evaluated to determine whether injection of polyA particles with various components promotes neutrophil and particle accumulation and liver damage in ALI / ARDs mice. Whole organ scans of parts of the liver are used to detect particle localization. Liver sections are homogenized and evaluated for particles, leukocyte populations, and expression of inflammation-related cytokines. Liver tissue / cell structure will be assessed via H&E staining, and liver function tests (LFTs) will be performed on serum from blood collected at euthanasia, including aspartate aminotransferase, alkaline phosphatase bilirubin, and alanine aminotransferase, as further measures of potential particle-induced liver damage in the ALI model. Controls will be livers from ALI / ARDs mice without particle treatment, and vehicle controls.
[0053] In some embodiments, the composition of the polyA particles of the present invention is optimized for therapeutic benefit. The additional benefit of SA released from polyA particles is evaluated for changes in BALF cell counts and cytokine levels by varying the rate of polyA polymer degradation from non-degraded polymers to polymers that substantially degrade within a few days. Figure 8 shows the structure of polyA polymers, where "R" corresponds to a linker ranging from linear hydrocarbon, e.g., (CH2)3, to branched aliphatic, and "n" is the polymer repeat unit. Particles made from polyA polymers with R1 and R2 adipic acid linkers completely degrade in 3 and 21 days, respectively (Rosario-Melendez, R., MAOuimet, and KEUhrich, Formulation of salicylate-based poly(anhydride-ester) microspheres for short- and long-term salicylic acid delivery. Polym Bull (Berl), 2013. 70(1): p. 343-351). Particles with R3 linker release 21% SA over 21 days and reach complete degradation within 3.5 months. In certain embodiments, both "R" and "n" are adjusted to achieve a polymer for formulating 2 μm VTP that substantially degrades in 3 days (R1), 7 days (R2), 21 days (R2-baseline polymer), and >28 days (R3) (Prudencio, A., R. C. Schmeltzer, and KEUhrich, Effect of Linker Structure on Salicylic Acid-Derived Poly(anhydride-esters). Macromolecules, 2005. 38(16): p. 6895-6901). In some embodiments, polyA particle degradation profile is determined via an assay using microspheres that degrade in plasma. Particles are added to plasma at a concentration based on the fraction of injected particles identified in the lung. PolyA particles with different degradation rates are matched with anti-ICAM-1 antibodies and injected into P. aeruginosa-infected mice 18 hours after infection. Mice are euthanized 24 hours after infection.Blood, BALF, and tissues are collected to measure the effect of polyA degradation rate on cell counts, cytokine and protein levels, and bacterial CFU.Controls are infected mice treated with (1) aspirin in DMSO (100ug / g), (2) DMSO only, (3) non-degradable polystyrene (PS) particles, and (4) degradable PLGA particles that release lactic acid instead of SA.
[0054] In some embodiments, the elements of the polyA particles of the present invention are optimized for neutrophil phagocytosis (e.g., rod shape). Surface protein expression and cytokine secretion by primary blood leukocytes (e.g., neutrophils, monocytes, and lymphocytes) are measured with or without exposure to polyA particles. Mouse whole blood and isolated cells are incubated with, for example, 3-day and >28-day degradable polyA particles for 1 hour. Particle-incubated cells are analyzed via flow cytometry to measure the amount of polyA particles internalized via fluorescent antibody staining, and expression levels of LAMs, e.g., CD26L, CD15, CD11b, and CD66b. Additionally, leukocytes are evaluated for apoptotic markers including annexin V, caspases, and phosphatidylserine. Supernatants are characterized via ELISA for pro-inflammatory factors released by isolated cells after phagocytosis. Controls are blood / cells exposed to PS particles and vehicle (no particles). Supernatants from particle-treated isolated primary cells are used to treat macrophages and dendritic cells (DCs) isolated from the lungs and to identify factors secreted by neutrophils (or monocytes or lymphocytes) exposed to polyA particles that are associated with an anti-inflammatory phenotype compared to PS particles or vehicle-only controls. Mouse lung macrophage expression of inflammatory cytokines is unchanged when directly incubated with polyA (Figure 9). Lung macrophages and DCs are isolated from dispersed lung digestive cells. (Deng, JC, G. Cheng, MW Newstead, X. Zeng, K. Kobayashi, RA Flavell, and TJ Standiford, Sepsis-induced suppression of lung innate immunity is mediated by IRAK-MJ Clin Invest, 2006.116(9):p.2532-42). Isolated macrophages and DCs are cultured with LPS (1 h) or P. aeruginosa (8 h) before being exposed to cell released supernatants for an additional 2 h. Control assays are untreated and LPS only / P. aeruginosa macrophages and DCs.Macrophage and DC supernatants will be assessed for factors secreted during ALI / ARDS, including IL-6, IL-10, IP-10, KC, MCP-1, MIP2, and TNF-α.
[0055] In some embodiments, the polymer particles of the present invention comprise polyA polymer particles. In other embodiments, the polymer particles comprise PLGA polymer particles. The polymer particles of the present invention are not limited to polyA, PS or PLGA particles. In certain embodiments, the polymer particles comprise additional polymers that are biodegradable, targetable and configured for administration of microparticles and / or nanoparticles.
[0056] In some embodiments, the polyA particles of the present invention are produced using an emulsion solvent evaporation method. In certain embodiments, polyvinyl alcohol (PVA) (e.g., 87-90% hydrolyzed PVA with an average Mw of 20-70 dDa) is dissolved in water to provide a 1 wt% PVA solution at pH 6-7. PolyA (e.g., 20 mg of polyA) is dissolved in dichloromethane (DCM) and the polyA in the DCM oil phase is slowly added to the PVA aqueous phase while mixing at 4000 rpm or higher for 1-2 hours or more. The produced particles are then centrifuged and the PVA / water solution is aspirated. The pellet is resuspended in deionized water, washed, frozen under liquid nitrogen, lyophilized, and stored at -20°C.
[0057] In some embodiments, the polyA particles of the present invention are modified to be carriers of one or more bioactive compounds or drugs. In certain embodiments, emulsion solvent evaporation (ESE) techniques are used to create drug-loaded degradable microparticles, e.g., microspheres from polyA polymer. For hydrophobic compounds and drugs, a single emulsion process is used in which the compound or drug is added to polyA polymer (Mw=about 20 kDa) dissolved in dichloromethane (oil phase) and the solution is emulsified in 1 wt% aqueous PVA solution. The oil phase (polyA and compound or drug) is slowly injected through a syringe needle and the emulsion is stirred continuously for up to 2 hours, allowing the oil droplets to harden. The resulting polyA particles are washed twice via centrifugation and dried via lyophilization. The particles are stored at -40°C until use. For hydrophilic drugs, a double emulsion process (water-in-oil-in-water) is used. The compound or drug is added to the aqueous phase where it is emulsified in polyA polymer dissolved in dichloromethane. The drug-polymer emulsion is then emulsified in an aqueous solution of 1 wt % PVA.
[0058] Pharmaceutical compositions comprising at least one polyA particle as described herein and at least one pharma- ceutically acceptable carrier may also contain one or more other active agents.The polyA particles as described herein may be utilized in any pharma- ceutically acceptable dosage form, including, but not limited to, injectable dosage forms, liquid dispersions, gels, aerosols, ointments, creams, lyophilized formulations, dry powders, tablets, capsules, controlled release formulations, fast melt formulations, delayed release formulations, sustained release formulations, pulsatile release formulations, immediate release and controlled release mixed formulations, etc. Specifically, the poly A particles described herein can be formulated (a) for administration selected from any of oral, pulmonary, intravenous, intraarterial, intrathecal, intraarticular, rectal, ocular, intracolonic, parenteral, intracisternal, intravaginal, intraperitoneal, topical, buccal, nasal, and local administration (e.g., dermal, mucosal, conjunctival, and / or topical administration); (b) in a dosage form selected from any of liquid dispersions, gels, aerosols, ointments, creams, tablets, sachets, and capsules; (c) in a dosage form selected from any of lyophilized formulations, dry powders, fast melt formulations, controlled release formulations, delayed release formulations, sustained release formulations, pulsatile release formulations, and mixed immediate and controlled release formulations; or (d) in any combination thereof.
[0059] Solutions or suspensions used for parenteral, intradermal, or subcutaneous application may contain one or more of the following components: (1) a sterile diluent such as water for injection, saline, fixed oils, polyethylene glycols, glycerin, propylene glycol, or other synthetic solvents; (2) an antibacterial agent such as benzyl alcohol or methylparabens; (3) an antioxidant such as ascorbic acid or sodium bisulfite; (4) a chelating agent such as ethylenediaminetetraacetic acid; (5) a buffer such as acetate, citrate, or phosphate; and (5) an agent for adjusting the tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases such as hydrochloric acid or sodium hydroxide. Parenteral preparations can be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass or plastic.
[0060] Pharmaceutical compositions suitable for injectable use may include sterile aqueous solutions (if water soluble), or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF, Parsippany, NJ), or phosphate buffered saline (PBS). In all cases, the composition should be sterile and fluid to the extent that easy syringability exists. Pharmaceutical compositions must be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The term "stable" as used herein means remaining in a state or condition suitable for administration to a subject.
[0061] The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by maintaining the required particle size in the case of dispersion, and by the use of surfactants. Prevention of microbial action can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it is preferable to include isotonic agents in the composition, for example, sugars, polyalcohols such as mannitol or sorbitol, and inorganic salts such as sodium chloride. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.
[0062] Sterile injectable solutions can be prepared by incorporating an appropriate amount of active agent (e.g., polyA particles) in a suitable solvent containing one or a combination of the above listed ingredients as desired, followed by filtered sterilization. In general, dispersions are prepared by incorporating at least one polyA particle into a sterile vehicle containing a basic dispersion medium and any other desired ingredients. In the case of sterile powders for preparing sterile injectable solutions, representative preparation methods include vacuum drying and freeze-drying, both of which obtain a powder of polyA particles and any additional desired ingredients from a previously sterile-filtered solution thereof. Oral compositions generally include an inert diluent or an edible carrier. For example, they can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, polyA particles can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, where the compound in the fluid carrier is applied orally, swirled in the mouth, and spat out or swallowed. Pharmaceutically compatible binding agents, and / or adjuvant materials can be included as part of the composition.
[0063] For administration by inhalation, the compound is delivered in the form of an aerosol spray from a pressured container or dispenser containing a suitable propellant, for example, a gas such as carbon dioxide, atomized liquid, or dry powder from a suitable device. For transmucosal or transdermal administration, a penetrant appropriate to the barrier to be permeated is used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be achieved by using nasal sprays or suppositories. For transdermal administration, the active agent is formulated into ointments, salves, gels, or creams as generally known in the art. The agent can also be prepared in the form of suppositories (e.g., using conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
[0064] In some embodiments, polyA particles are prepared with carriers that protect them from rapid elimination from the body. For example, controlled release formulations can be used, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparing such formulations will be apparent to those skilled in the art. Materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
[0065] Liposomal suspensions (including liposomes targeted to infected cells using monoclonal antibodies against viral antigens) may also be used as pharma- ceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
[0066] In addition, the suspension of polyA particles can be prepared as a suitable oil injection suspension.Suitable lipophilic solvent or vehicle includes fatty oil such as sesame oil, or synthetic fatty acid ester such as ethyl oleate, triglyceride or liposome.Non-lipid polycationic amino polymers can also be used for delivery.Optionally, the suspension can contain suitable stabilizers or agents that increase the solubility of compound and allow the preparation of highly concentrated solutions.
[0067] In some embodiments, it is particularly advantageous to formulate oral or parenteral compositions into dosage unit forms for ease of administration and uniformity of dosage. Unit dosage form, as used herein, refers to physically discrete units suitable as unitary dosages for subjects to be treated, each unit containing a predetermined amount of polyA particles calculated to produce a desired therapeutic effect in association with the required pharmaceutical carrier. The specifications of dosage unit forms of polyA particles described herein are governed by and directly depend on the characteristics of the particular polyA VTP and the particular therapeutic effect to be achieved, as well as the limitations inherent in the art of formulating such active agents for the treatment of individuals.
[0068] The pharmaceutical composition comprising at least one polyA particle can comprise one or more pharmaceutical excipients.Examples of such excipients include, but are not limited to, binders, fillers, lubricants, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients.Such excipients are known in the art.Exemplary excipients include:(1) binders, including various celluloses and cross-linked polyvinylpyrrolidone, microcrystalline cellulose, e.g., AVICEL.PH101 and AVICEL.PH102, silicified microcrystalline cellulose (ProSolv SMCC), tragacanth gum, and gelatin; (2) fillers, such as various starches, lactose, lactose monohydrate, and lactose anhydrous; (3) disintegrants, such as alginic acid, Primogel, corn starch, lightly cross-linked polyvinylpyrrolidone, potato starch, corn starch, and modified starches, croscarmellose sodium, crospovidone, sodium starch glycolate, and mixtures thereof; (4) lubricants, including agents that affect the flowability of the powder being compressed, such as magnesium stearate, colloidal silicon dioxide, e.g., AEROSIL.RTM. (5) lubricants such as colloidal silicon dioxide; (6) preservatives such as potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl alcohol or benzyl alcohol, phenolic compounds such as phenol, or quaternary compounds such as benzalkonium chloride; (7) diluents such as pharma- ceutical acceptable inert fillers such as microcrystalline cellulose, lactose, dibasic calcium phosphate, saccharides, and / or mixtures of any of the foregoing; examples of diluents include AVICEL. PH101 and AVICEL.PH102; lactose, such as lactose monohydrate, lactose anhydrous, and PHARMATOSE.DCL21; dicalcium phosphate, such as EMCOMPRESS; mannitol; starch; sorbitol; sucrose; and glucose; (8) sweeteners, including any natural or artificial sweetener, such as sucrose, saccharin, sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame; (9) flavorings, such as peppermint, methyl salicylate, orange flavor, MAGNASWEET (a trademark of MAFCO), bubble gum flavor, fruit flavor, and (10) effervescent agents, including effervescent couples, such as an organic acid and a carbonate or bicarbonate.Suitable organic acids include, for example, citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, and alginic acid and anhydrides and acid salts.Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate.Alternatively, only the sodium bicarbonate component of the effervescent couple may be present.
[0069] In various embodiments, the formulations described herein are substantially pure. As used herein, "substantially pure" means that the active ingredient (e.g., polyA particles) is the predominant species present (i.e., on a molar basis, more abundant than any other individual species in the composition). In one embodiment, a substantially purified fraction is a composition in which the active ingredient accounts for at least about 50% (on a molar basis) of all macromolecular species present. Generally, a substantially pure composition will contain greater than about 80% of all macromolecular species present in the composition. In various embodiments, a substantially pure composition will contain at least about 85%, at least about 90%, at least about 95%, or at least about 99% of all macromolecular species present in the composition. In various embodiments, the active ingredient is purified to homogeneity (contaminant species cannot be detected in the composition by conventional detection methods), and the composition consists essentially of a single macromolecular species.
[0070] [Kits containing polyA polymer particle compositions] The present disclosure provides kits comprising any of the polyA particles described herein. Such kits may include, for example, (1) at least one polyA particle, and (2) at least one pharma- ceutically acceptable carrier, such as a solvent or solution. Additional kit components may include, for example, (1) any of the pharma- ceutically acceptable excipients identified herein, such as stabilizers, buffers, etc., (2) at least one container, vial, or similar device for holding and / or mixing the kit components, and (3) a delivery device.
[0071] In certain embodiments, the invention provides instructions for administering said inhibitors of inflammation (e.g., polyA) to a subject. In certain embodiments, the invention provides instructions for using the compositions included in the kit for treating a condition characterized by inflammation in a cell or tissue (e.g., providing a decision tree for the treating physician to correlate dosing, route of administration, and patient-specific characteristics with a therapeutic route of action). In certain embodiments, the invention provides instructions for using the compositions included in the kit for treating various medical conditions associated with inflammation (e.g., ALI / ARDS, sepsis, infection, arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis). In certain embodiments, the invention provides instructions for using the compositions included in the kit for treating various medical conditions associated with inflammation and / or autoimmune conditions.
[0072] [Treatment method] In some embodiments, provided herein is a method of preventing or treating a medical condition (e.g., alleviating one or more symptoms) through the use of polyA particles. The method includes administering a therapeutically effective amount of polyA particles to a subject in need thereof. The described polyA particles can also be used for prophylactic therapy. In some embodiments, the polyA particles are administered intravenously. The polyA particles used in the treatment method can be polyA VTP or nTP as described herein, or a pharma- ceutically acceptable salt thereof, or a prodrug thereof. The individual or subject can be any animal (domestic, livestock, or wild), including, but not limited to, cats, dogs, horses, pigs, and cattle, preferably human subjects. As used herein, the terms patient, individual, and subject can be used interchangeably.
[0073] As used herein, "treating" refers to the management and care of a patient for the purpose of treating a disease, condition or disorder, and includes administration of polyA particles to prevent the onset of symptoms or complications of a disease, condition or disorder in a patient, to alleviate symptoms or complications of a disease, condition or disorder, or to eliminate the existence of a disease, condition or disorder. More specifically, "treating" includes reversing, attenuating, mitigating, minimizing, inhibiting, or stopping at least one adverse symptom or effect of a disease (disorder) state, disease progression, disease causative agent, or other abnormal condition. Generally, treatment is continued as long as symptoms and / or pathology improve.
[0074] In some embodiments, the compositions and methods of the present invention are used to prevent, treat and / or ameliorate inflammatory diseases, malignant diseases, infectious diseases, autoimmune diseases, and / or other diseases or conditions involving neutrophil pathophysiology.Non-limiting exemplary inflammatory diseases that can be treated with the polyA particles described herein include rheumatoid arthritis, juvenile idiopathic arthritis, systemic onset juvenile idiopathic arthritis, gout, osteoarthritis, sepsis, asthma, interstitial lung disease, inflammatory bowel disease, systemic sclerosis, intraocular inflammation, Graves' disease, endometriosis, systemic sclerosis, adult onset venous disease, amyloid A amyloidosis, polymyalgia rheumatica, seronegative remitting symmetric synovitis with pitting edema tending to improve spontaneously, Behcet's disease, uveitis, graft-versus-host disease, and TNFR-associated periodic syndrome.Malignant diseases that can be treated with the polyA particles described herein include cancer and cancer-related conditions. Non-limiting exemplary cancers include multiple myeloma, leukemia, pancreatic cancer, breast cancer, colorectal cancer, cachexia, melanoma, cervical cancer, ovarian cancer, lymphoma, gastrointestinal, lung cancer, prostate cancer, renal cell carcinoma, metastatic renal cancer, solid tumors, non-small cell lung cancer, non-Hodgkin's lymphoma, bladder cancer, oral cancer, myeloproliferative neoplasms, B-cell lymphoproliferative disorders, and plasma cell leukemia. Non-limiting exemplary cancer-related conditions include non-small cell lung cancer-related fatigue and cancer-related anorexia. Non-limiting exemplary infections that can be treated with the polyA particles described herein include bacterial infections, viral infections, fungal infections, rickettsia infections, parasitic infections, human immunodeficiency virus (HIV) infections, human T-lymphotropic virus (HTLV) infections, respiratory viral infections, cerebral malaria, urinary tract infections, and meningococcal infections. Non-limiting exemplary autoimmune diseases that may be treated with the Poly A VTPs described herein include systemic erythromatosis, systemic sclerosis, polymyositis, vasculitic syndromes including giant cell arteritis, Takayasu phlebitis, cryoglobulinemia, antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis to myeloperoxidase, rheumatoid vasculitis, Crohn's disease, relapsing polychondritis, acquired hemophilia A, and autoimmune hemolytic anemia.Additional diseases that may be treated with the polyA particles described herein include, but are not limited to, Castleman's disease, ankylosing spondylitis, coronary heart disease, rheumatoid arthritis cardiovascular disease, pulmonary arterial hypertension, chronic obstructive pulmonary disease (COPD), atopic dermatitis, psoriasis, sciatica, type II diabetes mellitus, obesity, giant cell arteritis, acute graft-versus-host disease (GVHD), non-ST elevation myocardial infarction, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, neuromyelitis optica, chronic glomerulonephritis, and Takayasu's arteritis.
[0075] In some embodiments, the disclosed compounds or their pharma- ceutically acceptable salts, or prodrugs, can be administered in combination with other active agents.The disclosed compositions comprising polyA particles can, for example, contain two or more polyA particles.In some embodiments, compositions containing one or more polyA particles are administered in combination with one or more additional agents for preventing, treating, and / or ameliorating inflammatory disease, malignant disease, infectious disease, autoimmune disease, and / or other diseases or conditions involving neutrophil pathophysiology.
[0076] Dosage regimens utilizing polyA particles are selected according to a variety of factors, including, for example, the type, species, age, weight, sex, and condition of the subject, the severity of the condition being treated, the route of administration, the renal and hepatic function of the subject, and the particular polyA particles or carriers thereof used. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the composition required to prevent, combat, or arrest the progression of the condition. In general, dosages, i.e., therapeutically effective amounts, range from about 1 ng / kg to about 1 g / kg body weight per day, in some embodiments from about 1 ug / kg to about 1 g / kg body weight, in some embodiments from about 1 ug / kg to about 100 mg / kg body weight, and in some embodiments from about 1 ug / kg to about 10 mg / kg body weight.
[0077] [Diagnostic and detection methods] The polyA particles described herein are used as diagnostic reagents either in vitro or in vivo.The polyA particles identified herein can be used in any diagnostic, detection, imaging, high throughput screening, or target validation technique or procedure, or assay, and the polyA particles can be used without limitation.
[0078] The polyA particles capable of binding to inhibitory neutrophils described herein can be used in a variety of assays, including assays using planar arrays, beads, and other types of solid supports. The assays can be used in a variety of contexts, including life science research applications, clinical diagnostic applications (e.g., diagnostic tests for disease, or "wellness" tests for preventive health care), affinity binding oligonucleotide nuclease assays (ALONA), and ubiquitin-proteasome system (UPS) assays, as well as in vivo imaging applications. In some applications, multiplex assays employing the described polyA VTPs may be used.
[0079] In some embodiments, the polyA particles are used as a sensitive and specific reagent for incorporation into various in vitro diagnostic methods or kits. In some embodiments, the polyA particles are used as an alternative to antibodies in some infectious or other types of disease detection methods, and the polyA particles include a detectable material and either or both of an immobilization or capture component. In these embodiments, various assay formats can be utilized after mixing the polyA particles from the kit with a clinical specimen. In one embodiment, the polyA particles also include a detectable label, such as a fluorophore. In other embodiments, the assay format may include fluorescence quenching, hybridization methods, flow cytometry, mass spectrometry, inhibition or competition methods, enzyme-linked oligonucleotide assays, SPR, evanescent wave methods, and the like. In some embodiments, the polyA particles are provided in the kit in solution. In other embodiments, the polyA particles in the kit are immobilized on a solid support that is used in conjunction with an assay to test the specimen. In various embodiments, the solid support is designed for detection of one or more targets of interest. In other embodiments, the kit may further comprise reagents for extracting targets of interest, reagents for assembling polyA particles, reagents for performing washes, detection reagents, and the like.
[0080] Also provided are diagnostic or assay devices (e.g., columns, test strips or biochips) having one or more polyA particles attached to a solid surface of the device. The polyA particles can be positioned so as to be capable of binding to neutrophils in contact with the solid surface, forming polyA particle-neutrophil complexes that remain attached to the surface of the device, thereby capturing the target and allowing detection and optional quantification of the target. An array of polyA particles (which may be the same or different) may be provided on such a device.
[0081] In one embodiment for detecting neutrophils, the polyA particles are contacted with a labeling agent that includes a binding partner specific for neutrophils. The specific binding partner can be any suitable moiety, including antibodies, antibody fragments, synthetic antibody mimics, biomimetics, aptamers, molecularly imprinted ligands, and the like. The specific binding partner is conjugated or linked to another labeling agent component, usually a detectable moiety or label.
[0082] Detectable moiety or label can be directly or indirectly detected. Generally, any reporter molecule that can be detected can be a label. Labels include, for example, (i) reporter molecules that can be directly detected by generating a signal, (ii) specific binding pair members that can be indirectly detected by subsequent binding to cognate reporter molecules, (iii) mass tags that can be detected by mass spectrometry, (iv) oligonucleotide primers that can provide templates for amplification or ligation, and (v) specific polynucleotide sequences or recognition sequences that can act as ligands, such as repressor proteins, in the latter two cases, oligonucleotide primers or repressor proteins will have or can have reporter molecules, etc. The reporter molecule may be a catalyst, such as an enzyme, a polynucleotide encoding the catalyst, a promoter, a dye, a fluorescent molecule, a quantum dot, a chemiluminescent molecule, a coenzyme, an enzyme substrate, a radioactive group, a small organic molecule, an amplifiable polynucleotide sequence, a particle such as latex or carbon particles, a metal sol, a crystal, a liposome, a cell, etc. (which may or may not be further labeled with a dye, a catalyst, or other detectable group); a mass tag that changes the weight of the molecule to which it is conjugated for mass spectrometry purposes, etc. The label may be selected from an electromagnetic or electrochemical material. In one embodiment, the detectable label is a fluorescent dye. Other labels and labeling schemes will be apparent to one of skill in the art based on the disclosure herein. EXAMPLES
[0083] The invention having been generally described will be more readily understood by reference to the following examples, which are included solely for purposes of illustrating certain aspects and embodiments of the invention and are not intended to limit the invention. All protocols for animal and human studies were approved by the Committee on Use and Care of Animals or the Institutional Review Board of the University of Michigan.
[0084] Example 1 - PolyA particles reduce neutrophil pulmonary migration during ALI. PolyA microspheres were injected into the tail vein of mice with 30 mg / kg LPS-induced ALI. PolyA spheres injected 1 h after LPS administration significantly reduced BALF neutrophil counts compared to ALI mice without particles (Figure 3). Tail vein injection of aspirin in DMSO did not reduce BALF neutrophil counts in ALI mice, demonstrating the utility of physical interaction of PolyA VTP particles with neutrophils in the observed reduction in neutrophil lung migration in ALI. Particle-treated ALI mice had lower albumin levels in BALF (Figure 16), indicating reduced lung injury due to particle infusion. Levels of markers of inflammation typically found in the BALF of ALI mice indicated that PolyA spheres significantly reduced inflammation in the lungs compared to PS or aspirin (p<0.05). BALF concentrations of TNF-α, KC (FIG. 15), and MIP2 (FIG. 16) were reduced in polyA-treated ALI mice, but not in mice treated with PS spheres or aspirin.
[0085] Example 2 - PolyA MPs do not exacerbate bacterial infection in mice with bacterial-induced ALI. To determine whether polyA MPs have utility in the clinical setting of ALI / ARDS, i.e., whether polyA MP therapy works without affecting the host's ability to clear the primary infection, a murine model of ALI / ARDS infected with Pseudomonas (P.) aeruginosa was investigated. Mice were infected with P. aeruginosa via intratracheal (it) inoculation. P. aeruginosa bacteria grown in Difco broth were diluted to the desired concentration. Mice were anesthetized with ketamine and xylazine by the intraperitoneal route, the trachea was exposed, and 30 μl of inoculum (7–8 × 10 5CFU) or saline was administered via a sterile 26-gauge needle. Either 6 or 18 hours post-infection, polyA MP was injected intravenously (IV, tail vein) and mice were euthanized 24 hours post-infection. At 24 hours post-infection, blood CFU was significantly lower in polyA MP-treated mice than in untreated mice for both the 6 and 18 hour injection points (Figure 4). The results in Figure 5 show that injection of polyA MP at 18 hour intervals reduced neutrophils in the lung BALF at the time of sample collection at 24 hours. Conversely, neutrophil counts in the BALF of polyA MP injections at 6 hour intervals were the same as those of untreated infected mice. These data indicate that polyA MP does not adversely affect the host's ability to clear the primary lung infection. In line with the BALF neutrophil data, polyA MP treatment at 18 hour intervals prevented the systemic spread of infection and no traces of P. aeruginosa were found in the blood at 24 hours post-infection. Lower concentrations of TNF-α (FIG. 4), IL-6, KC, and MCP-1 in BALF with polyA MP treatment were observed (FIG. 16). Taken together, these data indicate that the timing of particle infusion is important for efficiency in treating ALI. Given the lower BALF neutrophil counts at 24 hours for particle treatment at 18 hours post-infection and 6 hours post-infection, extending the interval after bacterial infection but before particles are infused may underlie the therapeutic effect. Although the present invention is not limited to a particular mechanism(s), a minimal number of neutrophils may initially enter the lung tissue to facilitate bacterial clearance, but before extensive damage is done to the lung. PolyA MP then halts neutrophil lung migration, reducing damage while allowing natural host immunity or active pharmaceutical ingredients (APIs) to clear the primary infection.
[0086] Example 3 - Neutrophil-PolyA MP interaction in LPS-induced lung injury model. To determine whether PolyA MP administration attenuates neutrophil infiltration into the lung in a mouse model of ALI and to determine whether PolyA MP particles have a therapeutic advantage compared to polystyrene (PS) particles and vehicle controls, an LPS-induced model of ALI was used and the % of total BALF cells, BALF neutrophils and macrophages, and inflammatory cytokine concentrations were quantified and compared.
[0087] [Particle Decomposition] 1 x 10 as determined by manual counting on a hemocytometer 7 PolyA nTP particles were suspended in 10 mL of PBS- / - and placed under rotation at 37°C (Figure 10). The particles were centrifuged and the supernatant was continuously removed and replaced. The supernatant was then added to a 96-well plate and the fluorescence intensity was measured (ex=315 nm, and em=408 nm for salicylic acid). The cumulative fluorescence intensity at each time point is plotted against the degradation time in Figure 12 (MFI=mean fluorescence intensity).
[0088] [Acute lung injury (ALI) model] Male BALB / c or C57BL / 6J mice were anesthetized with inhaled isoflurane and administered 50 uL of 0.4 mg / mL LPS intratracheally to induce pulmonary inflammation. 8 ) were injected via a tail vein catheter either 2 or 6 hours post-infusion. Methods for euthanasia and sample processing are shared with the P. Aeruginosa model (below), except that instead of cytospun BALF, cells were stained with CD45, CD11b, and Ly6G and fixed overnight prior to flow cytometry to determine the percentage of neutrophils and macrophages in each sample.
[0089] [result] PolyA nTP administration reduced neutrophil infiltration and inflammatory cytokine concentrations in the lung after LPS, indicating attenuation of the neutrophil-mediated inflammatory response (Figures 14, 15, and 16). Both PS and polyA nTP reduced neutrophil infiltration into the lung after LPS, but only polyA MP reduced the concentration of inflammatory cytokines in the lung (Figures 17, 18, 19, 20, 21, and 22).
[0090] [Example 4 - Optimal administration interval] To characterize the timeline of neutrophil influx into the lungs and to identify the optimal injection interval after infection for maximum therapeutic benefit, a model of intratracheal LPS administration in C57BL / 6J mice was used for analysis of BALF samples (Figure 23). Neutrophil influx into the alveolar airspace is maximal between 2 and 6 hours post-injection. A polyA MP administration interval of 2 hours post-injection results in the greatest reduction in neutrophil infiltration in animals under these conditions (Figures 24, 25, 26, 27, 28, and 29) (neutrophil NΦ and macrophage MΦ).
[0091] Example 5 - Therapeutic Benefits of PolyA MP Administration The therapeutic benefit of polyA MP administration was identified using a bacterial model of ALI / ARDS in which mice were infected with P. aeruginosa and polyA MP was administered parenterally 6 and 18 hours after infection.
[0092] [method] <Particle preparation> PolyA particles were prepared using a single emulsion solvent evaporation (ESE) method. 20 mg of PolyA polymer was dissolved in 20 mL of dichloromethane. Then, 75 mL of 1% polyvinyl alcohol (PVA) solution was placed on a mixer at 4250 rpm. The PolyA solution was slowly injected into the PVA solution and mixed for 2 hours. After mixing, the solution was allowed to settle for approximately 45 minutes to remove the particles, which were then washed by centrifugation three times with DI water. The particles were then lyophilized and stored at -40°C until use. Particle size was determined by scanning electron microscopy (SEM) and dynamic light scattering (DLS), and particle concentration was determined by counting in a hemocytometer.
[0093] <Bacteria growth> P. aeruginosa cultures were grown overnight in Difco nutrient broth at 37° C. under constant shaking. The concentration of bacteria in the broth was determined by measuring the light absorbance at 600 nm and then plotting the optical density (OD) on a standard curve generated with known colony forming units (CFU).
[0094] <Intranasal bacterial inoculation> Mice were anesthetized by intraperitoneal injection of a ketamine / xylazine mixture and pulmonary infection was induced by intranasal administration of 30 uL of bacterial solution (15 uL in each nostril) (Figure 30).
[0095] <PolyA VTP injection> Six or 19 hours after infection, mice were placed in a restrainer and a catheter was inserted into the tail vein. Each mouse received 2x10 particles in an injection volume of 100 uL at a dose of approximately 30 mg / kg (Figure 30).
[0096] <Euthanasia and sample processing> 24 hours after infection, mice were euthanized by CO2 overdose. After euthanasia, the thoracic cavity was exposed and blood was collected using cardiac puncture. The trachea was exposed and opened and the lungs were washed with 3 mL of PBS- / - to remove cells in the alveolar air spaces. BALF samples were centrifuged and the supernatants were stored at -80°C for ELISA to quantify inflammatory cytokines. The cell pellet was resuspended in 500uL of RPMI medium and an aliquot was diluted 1:1 with Turk Blood Diluting Fluid and counted by hemacytometer. Cytospin samples were prepared and cells were stained to distinguish neutrophils from mononuclear cells. Blood and BALF samples were placed on agar plates and grown overnight at 37°C to determine CFU. Blood was centrifuged and plasma samples were collected and stored at -80°C for ELISA analysis.
[0097] [result] Compared to P. aeruginosa infected but untreated control mice, polyA MP administration at 6 and 18 hours reduced lung concentrations of IL-6, IL-10, KC, MIP2, MCP1, and TNF-α cytokines, indicating reduced lung inflammation after polyA VTP treatment (Figures 31, 32, and 33). PolyA MP treatment 18 hours after infection significantly reduced the number of neutrophils in BALF, whereas administration 6 hours after infection did not (Figure 34). PolyA MP treatment 18 hours after infection reduced bacterial CFU in the blood indicating that the treatment plays a role in limiting infection to the lungs.
[0098] Example 6 - Therapeutic Benefits of PolyA MP Administration To ensure that PolyA MP caused a reduction in bacterial CFU blood counts, the method of Example 5 was repeated with PolyA MP particle administration at 18 hours in parallel with a saline intravenous (IV) control. PolyA MP administration, but not saline, reduced CFU in the blood compared to infected controls, indicating that PolyA MP contains the infection to the lungs and prevents systemic spread of the infection.
[0099] Example 7 - Time course of pulmonary neutrophil infiltration after infection To measure the course of neutrophil influx into the lungs after infection, BALF cell counts, BALF P. aeruginosa 19660 counts, and blood P. aeruginosa 19660 counts were measured 12, 18, 24, 30, and 36 hours after infection. A significant increase in BALF cells was observed between 12 and 24 hours, with an associated increase in both lung and blood P. aeruginosa CFU counts (Figures 35 and 36).
[0100] Example 8 - Therapeutic Benefit of PolyA MPs on Survival After Infection To determine whether administration of polyA MP particles positively affected survival after infection, mice were infected with P. aeruginosa and half of the mice were given polyA particles 18 hours after infection. PolyA MP significantly reduced mortality in infected mice (Figure 37).
[0101] Example 9 - Conjugation of PolyA Particles To ensure that the PolyA particles contained sufficient carboxyl groups on the surface to conjugate targeting ligands, 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (EDC) chemistry was used to conjugate Neutravidin, followed by binding of biotinylated anti-ICAM-1 to the surface of the particles. 2 μm PolyA particles were suspended in 50 mM MES buffer and counted using a hemocytometer. 2.2 × 10 9 10 particles were suspended in 400uL of 5mg / mL Neutravidin solution in 50mM MES. The particles were rotated for 15 minutes, after which 400uL of 75mg / mL EDC solution was added and the particles were rotated overnight. 4mg of glycine was then added to the particle solution to quench the reaction and the particles were rotated for 15 minutes. The particles were then centrifuged and resuspended in PBS- / -. After Neutravidin conjugation, 1x107 particles were incubated in 100uL of 5mg / mL biotinylated anti-ICAM-1 in PBS- / - with 2% BSA for 1 hour with rotation. The avidin particles were then stained with biotin-PE and the anti-ICAM particles were stained with goat anti-mouse IgG-fluorescein isothiocyanate (FITC). The particles were then measured on an Attune Flow Cytometer and compared to R-Phycoerythrin (R-PE) and FITC molecules on equivalent soluble fluorochrome (MESF) beads to determine the total number of ligand sites on the particle surface. Figure 38 shows the flow cytometry histogram plots. PolyA-avidin and PolyA anti-ICAM each had 36,819 sites / um. 2 and 43,235 sites / um 2 It was.
[0102] [Equivalent] The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The foregoing embodiments are therefore to be considered in all respects as illustrative rather than limiting the invention described herein. The scope of the invention is therefore indicated by the appended claims rather than the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.
[0103] [Incorporated by reference] All publications, published patent documents, and patent applications cited in this specification are herein incorporated by reference to the same extent as if each individual publication, published patent document, or patent application was specifically and individually indicated to be incorporated by reference herein.
Claims
1. 1. Use of salicylic polyanhydride (poly A) particles which hydrolyze to salicylic acid in the manufacture of a medicament for treating, alleviating, or preventing the recurrence of a neutrophil mediated condition in a patient, comprising: The polyA particle is a vascular targeted polyA particle (VTP), the surface of which is coupled to an antibody or ligand that targets one or more proteins expressed on the vascular wall.
2. 2. The use of claim 1, wherein the neutrophil-mediated condition is one or more conditions selected from vascular thrombosis, inflammatory arthritis, systemic lupus erythematosus (SLE), atherosclerosis, infection, sepsis, acute lung injury arthritis (ALI), and acute respiratory distress syndrome (ARDS).
3. The use of claim 1, wherein the patient is a mammal.
4. The use according to claim 3, wherein the mammal is a human.
5. The use according to claim 1, wherein the medicament is suitable for intravascular administration.
6. The use according to claim 5, wherein the administration is intravenous administration.
7. The use according to claim 5, wherein the medicament is suitable for administration using a guide catheter.
8. The use according to claim 1 , wherein the polyA particles are microparticles.
9. The use according to claim 1 , wherein the polyA particles are nanoparticles.
10. The use according to claim 1 , wherein the polyA particles are spherical.
11. The use according to claim 10, wherein the sphere comprises a smooth surface.
12. The use according to claim 1 , wherein the polyA particles comprise a variety of polyA particles differing in size, shape and / or surface morphology.
13. a pharmaceutical composition comprising polyA particles and instructions for administering said pharmaceutical composition to a patient diagnosed with vascular thrombosis, inflammatory arthritis, systemic lupus erythematosus (SLE), atherosclerosis, sepsis, acute lung injury arthritis (ALI), and acute respiratory distress syndrome (ARDS); The polyA particles are vascular targeted polyA particles (VTPs), the surface of which is coupled to an antibody or ligand that targets one or more proteins expressed on the vascular wall.
14. at least one polyA particle and a pharma- ceutically acceptable carrier and / or a pharma- ceutically acceptable formulation, The pharmaceutical composition, wherein the polyA particle is a vascular targeted polyA particle (VTP), and the surface of the VTP is bound to an antibody or ligand that targets one or more proteins expressed on the vascular wall.
15. A method for producing the pharmaceutical composition of claim 14, comprising the steps of: The at least one Poly A particle is a) dissolving polyvinyl alcohol (PVA) having an average molecular weight of 20-70 kDA in water to produce a 1 wt % PVA solution with a pH of 6-7; b) dissolving PolyA in dichloromethane (DCM); c) adding the PolyA in the DCM to the PVA solution over a period of at least 1 hour while mixing at >4000 rpm to form an emulsion; d) centrifuging the emulsion; e) aspirating the centrifuged solution from the centrifuged pellet; f) resuspending the pellet in deionized water to produce suspended Poly A particles; g) washing the suspended Poly A particles; h) freeze-drying the washed PolyA particles; and i) freezing said lyophilized polyA particles.
16. 16. A method of making a pharmaceutical composition according to claim 15, wherein the polyA particles are modified to be carriers of one or more hydrophobic bioactive compounds or drugs by adding said one or more hydrophobic bioactive compounds or drugs to the polyA polymer dissolved in the DCM.
17. 16. The method of claim 15, wherein the polyA particles are modified to be carriers of one or more hydrophilic bioactive compounds or drugs by adding one or more of said hydrophilic bioactive compounds or drugs to the aqueous phase which is emulsified in the polyA polymer dissolved in the DCM and emulsifying the drug-polymer emulsion in a 1 wt% aqueous PVA solution.
18. The pharmaceutical composition of claim 14, wherein the polyA particles are targeted polyA particles.
19. 20. The pharmaceutical composition of claim 18, wherein the targeted polyA particle is a polyA VTP particle.
20. A method for producing the pharmaceutical composition of claim 19, comprising the steps of: The polyA VTP particles are a) suspending polyA particles in 50 mM MES buffer; b) suspending the particles in a solution of Neutravidin in 50 mM MES; c) adding a 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride (EDC) solution to the suspended particles; d) adding glycerin to the solution containing the polyA particles; e) centrifuging the solution; f) resuspending the polyA particles in PBS; and j) incubating said solution containing said polyA particles with biotinylated anti-ICAM-1 in PBS- / - containing 2% BSA.
Citation Information
Patent Citations
Polyanhydrides with biologically active degradation products
JP2003511550A
Slow-degrading polymers for undelayed and sustained drug delivery
US20120058155A1
Therapeutic compositions for bone repair
US20140271864A1
